Short description
Anchiano is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer.
Description
Anchiano is a biopharmaceutical company that specializes in the development of Targeted Cancer Therapies for the treatment of numerous types of cancer. The Company's technology offers a safe and long-term treatment of cancer, with no adverse effects. BioCancell was co-founded in 2004 by Professor Avraham Hochberg, Professor of Molecular Biology at the Hebrew University of Jerusalem, based on technology developed by him over the past 25 years. The drug candidates developed by the Company are targeted and their goal is to selectively destroy the cancer cells without affecting healthy cells (‘Targeted Cancer Therapy'). The approach is based on the identification of target genes, such as H19, that are expressed only in cancerous tumors, and not in healthy cells, and on the use of those genes' regulatory sequences for the activation of a toxin inside the cancerous cells only, thus destroying them without harming healthy cells. BioCancell's leading drug candidate, BC-819, has completed a Phase IIb clinical trial for the treatment of bladder cancer, as well as additional clinical trials for other cancer indications. BioCancell’s Phase I clinical trial for BC-821, scheduled to commence in 2015, is a continuation of the success of pre-clinical studies that have examined the use of BC-821 as a treatment for several cancer indications
Last funding
Noway Youcantaccess
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Jerusalem, Yerushalayim, Israel, Asia
Founded on
January 1, 2004
Closed on
March 17, 2021
Exited on
February 12, 2019
Went public on
February 12, 2019
Delisted on
March 16, 2021
Stock symbol
ANCN
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$34056 - 789030
Sign in for full access
Investors
Blurry Noaccess, Nopepepe, Uh Ohhhh
Sign in for full access
Founders
Avraham Hochberg